1)Bruce SE, Yonkers KA, Otto MW, et al:Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder:A 12-year prospective study. Am J Psychiatry 162:1179-1187, 2005[PMID:15930067]
2)塩入俊樹,鎌倉理人:不安障害を見直す—慢性化・難治化と転帰—:パニック障害.精神科 21:528-537, 2012
3)Domschke K, Seuling PD, Schiele MA, et al:The definition of treatment resistance in anxiety disorders:A Delphi method-based consensus guideline. World Psychiatry 23:113-123, 2024[PMID:38214637]
4)Battaglia M, Bernardeschi L, Politi E, et al:Comorbidity of panic and somatization disorder:A genetic-epidemiological approach. Compr Psychiatry 36:411-420, 1995[PMID:8565445]
5)Schneier FR, Heckelman LR, Garfinkel R, et al:Functional impairment in social phobia. J Clin Psychiatry 55:322-331, 1994[PMID:8071299]
6)American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, 5th ed,Text Revision(DSM-5-TR). American Psychiatric Publishing, Washington DC, 2022[日本精神神経学会(日本語版用語監修),髙橋三郎,大野裕(監訳),染矢俊幸,神庭重信,尾崎紀夫,他(訳):DSM-5-TR精神疾患の診断・統計マニュアル,医学書院,2023]
7)高井健太朗,塩入俊樹:不安症群における寛解と再発,そして再発予防—パニック症,社交不安症,全般不安症について.精神科治療学 33:1079-1086, 2018
8)Wang PS, Berglund P, Olfson M, et al:Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:603-613, 2005[PMID:15939838]
9)Magee WJ, Eaton WW, Wittchen HU, et al:Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53:159-168, 1996[PMID:8629891]
10)Shindo M, Shioiri T, Kuwabara H, et al:Clinical features and treatment outcome in Japanese patients with social anxiety disorder:Chart review study. Psychiatry Clin Neurosci 60:410-416, 2006[PMID:16884440]
11)Christensen MC, Schmidt S, Grande I:Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder:Results of the RECONNECT study. J Psychopharmacol 36:566-577, 2022[PMID:35499104]
12)Bandelow B, Lichte T, Rudolf S, et al:The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int 111:473-480, 2014[PMID:25138725]
13)塩入俊樹:高齢発症の不安症.精神科治療学 39:511-518, 2024
14)塩入俊樹,桑原秀樹:不安症に対する新たな治療と薬物療法の位置付け.臨床精神薬理 18:1425-1435, 2015
15)辛島裕士,外須美夫:感覚とTRPチャネル.福岡医誌 102:48-55, 2011
16)Goettel M, Fuertig R, Mack SR, et al:Effect of BI 1358894 on cholecystokinin-tetrapeptide(CCK-4)-induced anxiety, panic symptoms, and stress biomarkers:A phase I randomized trial in healthy males. CNS Drugs 37:1099-1109, 2023[PMID:38019356]
17)Grimm S, Keicher C, Paret C, et al:The effects of transient receptor potential cation channel inhibition by BI 1358894 on cortico-limbic brain reactivity to negative emotional stimuli in major depressive disorder. Eur Neuropsychopharmacol 65:44-51, 2022[PMID:36343427]
18)Abreu AR, Molosh AI, Johnson PL, et al:Role of medial hypothalamic orexin system in panic, phobia and hypertension. Brain Res 1731:145942, 2020[PMID:30205108]
19)Salvadore G, Bonaventure P, Shekhar A, et al:Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry 10:308, 2020[PMID:32895369]